Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications
Christopher Kasia, Steven J. Scaglione – 30 April 2019
Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis
Silvia Nardelli, Barbara Lattanzi, Manuela Merli, Alessio Farcomeni, Stefania Gioia, Lorenzo Ridola, Oliviero Riggio – 30 April 2019 – Muscle alterations (myosteatosis and sarcopenia) are frequent in cirrhosis and related to some complications including overt hepatic encephalopathy (HE). The aim of our study was to investigate the relationship between muscle alterations and minimal HE (MHE) and their role in the risk of overt HE. Sixty‐four patients with cirrhosis were administered the Psychometric Hepatic Encephalopathy Score and animal naming test to detect MHE.
Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial
Jasmohan S. Bajaj, Nita H. Salzman, Chathur Acharya, Richard K. Sterling, Melanie B. White, Edith A. Gavis, Andrew Fagan, Michael Hayward, Mary L. Holtz, Scott Matherly, Hannah Lee, Majdi Osman, Mohammad S. Siddiqui, Michael Fuchs, Puneet Puri, Masoumeh Sikaroodi, Patrick M. Gillevet – 30 April 2019 – Hepatic encephalopathy (HE) can cause major morbidity despite standard of care (SOC; rifaximin/lactulose). Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect of FMT without antibiotics using the capsular route requires investigation.
Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock–Induced Liver Injury
Yang Xie, Meishu Xu, Meihong Deng, Zhigang Li, Pengcheng Wang, Songrong Ren, Yan Guo, Xiaochao Ma, Jie Fan, Timothy R. Billiar, Wen Xie – 30 April 2019 – Hemorrhagic shock (HS) is a life‐threatening condition associated with tissue hypoperfusion and often leads to injury of multiple organs including the liver. Pregnane X receptor (PXR) is a species‐specific xenobiotic receptor that regulates the expression of drug‐metabolizing enzymes (DMEs) such as the cytochrome P450 (CYP) 3A.
Maple Syrup Urine Disease and Domino Liver Transplantation: When and How?
Marco Spada, Roberta Angelico, Carlo Dionisi‐Vici – 30 April 2019
Letter to the Editor: The Kynurenine Pathway in Hepatic Cirrhosis
Abdulla Badawy – 29 April 2019
Reply
Patrick Starlinger, David Pereyra, Matthias Hackl, Alice Assinger – 29 April 2019
Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease
Rahima A. Bhanji, Aldo J. Montano‐Loza, Kymberly D. Watt – 29 April 2019 – Sarcopenia is a common complication of cirrhosis and is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function. Sarcopenia is associated with poor prognosis and increased mortality. How sarcopenia and muscle wasting relate to such poor outcomes requires looking beyond the overt muscle loss and at this entity as a systemic disease that affects muscles of vital organs including cardiac and respiratory muscles.
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander‐Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group – 29 April 2019 – Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed nations at risk of developing NASH cirrhosis and its complications.